BRCA status was known for 131 ( 96 % ) patients in the olaparib group versus 123 ( 95 % ) in the placebo group , of whom 74 ( 56 % ) versus 62 ( 50 % ) had a deleterious or suspected deleterious germline or tumour BRCA mutation .